Annolyse
BriefingsCompaniesInsightsPrinciplesCompareChatWatchlist

Explore

  • Briefings
  • Companies
  • Insights
  • Compare

Resources

  • Search
  • Methodology

© 2026 Annolyse.

ChartsAnalysisChatData
  1. Charts
  2. Analysis
  3. Chat
  4. Data
  5. Sources
←Back to briefings
Promisia Healthcare (PHL) / FY26

FY26 NPAT $12.9m hinges on H2 swing; EBITDAF $6.6m the cleaner read

Full-year Cromwell consolidation and a sharp H2 earnings swing lift reported NPAT while net debt/EBITDAF falls from 11.1x to 5.8x.

Healthcare / Aged care

PHL revenue trajectory

Revenue context before the current result.

↗
Loading chart...
FY26 was $40.1m, versus $29.9m in FY24.

PHL EBITDAF margin

EBITDAF margin across covered periods.

↗
Loading chart...
  • FY22 PHL: Outside range high ebitda margin. 23.5%; 3-period range 12.7% to 16.5%. EBITDA margin: 23.5%, above normal range; 3-period mean 14.7%, range 12.7%-16.5%.
EBITDA margin: 23.5%, above normal range; 3-period mean 14.7%, range 12.7%-16.5%.

PHL operating cash flow

Operating cash flow across covered periods.

↗
Loading chart...
FY26 was $6.4m, versus $7.5m in FY24.

PHL working-capital movement

Operating working-capital absorption or release by reporting period.

↗
Loading chart...
HY24 was $0.1m, versus $0.4m in FY23.
Release date
28 May 2026
Published
28 May 2026
Ask about this result
Sections⌄
  1. Charts
  2. Analysis
  3. Chat
  4. Data
  5. Sources

Key metrics

Numbers worth scanning first

FY26 vs FY25

Revenue

$40.1m

+29.1% ↑ vs $31.1m

Net profit after tax

$12.9m

+89.7% ↑ vs $6.8m

Net cash inflow from operating activities

$6.4m

+86.9% ↑ vs $3.4m

Full-year dividend per share

0.0c

— vs —

Profit before tax

$13.9m

+107.5% ↑ vs $6.7m

Cash and cash equivalents

$0.11m

-16.7% ↓ vs $0.13m

Total assets

$199.5m

+15.9% ↑ vs $172.1m

What changed

Promisia closed FY26 with revenue of $40.1m and reported net profit after tax of $12.9m, against $31.1m and $6.8m in the prior year

These headline movements are not a like-for-like read: the comparative included a part-period Cromwell contribution and a discontinued Eileen Mary operation, so the year-on-year growth rates carry a basis discontinuity. The cleaner operating anchor is underlying EBITDAF of $6.6m, which the company reconciles to $4.2m in the prior year. Operating cash flow rose to $6.4m from $3.4m, while gross borrowings fell to $38.6m from $46.7m and net debt to EBITDAF moved from 11.1x to 5.8x. A dividend policy was introduced but no FY26 dividend was declared.

What matters

EBITDAF of $6.6m sits well below profit before tax of $13.9m, a gap of roughly $7.3m that operating activity does not explain

The HY26 release reported H1 NPAT of -$0.0m, so essentially the entire reported full-year NPAT of $12.9m landed in H2 on H2 revenue of around $20.9m. This means investors should treat the PBT and NPAT lines as containing material non-operating items and use EBITDAF as the durable earnings reference.

Net debt fell by roughly $8m and net debt/EBITDAF improved from 11.1x to 5.8x. Leverage remains elevated for an aged-care operator, but the trajectory expands capacity for the acquisition activity flagged in the HY26 release.

Management set a dividend policy but declared no FY26 distribution. Operating free cash flow remained slightly negative at -$0.2m (per the company's OFCF reconciliation), and cash on balance sheet is $0.1m, so near-term distributable capacity is constrained even as the policy signals capital-return intent.

Expectations

No quantitative forward targets are disclosed

The release describes Cromwell as now embedded and Nelson Street as effectively full, and the HY26 release referenced early-stage acquisition negotiations. The result supports the operational repositioning narrative at the EBITDAF level, but with H2 carrying virtually all reported earnings and a basis change from the acquisition and disposal, the forward run-rate cannot be cleanly inferred from the headline. Investors should weight EBITDAF rather than NPAT when projecting forward, and watch HY27 for confirmation that the H2 EBITDAF pace (roughly $4.1m on the implied split) reflects an underlying base rather than seasonal occupancy strength.

Quality of result

The durable component is EBITDAF of $6.6m

Net cash from operations of $6.4m sits close to this number, so cash conversion at the EBITDAF level looks reasonable. Operating free cash flow improved to -$0.2m from -$1.3m, indicating that after capex of $0.5m, interest, and lease costs the business is roughly at cash breakeven - an improvement, but not yet a source of distributable surplus.

The less durable component is the gap between EBITDAF and reported PBT/NPAT. The H2 swing from a near-breakeven H1 to roughly $13.0m of H2 NPAT cannot be reconciled to EBITDAF and is consistent with property revaluation or other below-the-line gains typical for aged-care operators, though the source material provided does not separately disclose the driver. The effective tax rate of 7.3% (prior: 1.6%) is consistent with non-taxable or low-tax gains in that line, which reinforces the view that the NPAT growth is not a clean operating signal. The basis discontinuity from a full-year Cromwell consolidation against a part-period prior also affects revenue and earnings growth comparability.

Unresolved

Open questions

What specifically drove the H2 NPAT swing from near-breakeven in H1 to roughly $13.0m in H2, and how much was non-cash revaluation versus operating performance?
Why was a dividend policy set without an accompanying FY26 dividend, and what free-cash-flow threshold must be met before a first payment?
How does management define the steady-state EBITDAF base now that Cromwell is fully embedded and Eileen Mary fully removed?
What use of debt headroom is contemplated given net debt/EBITDAF at 5.8x and the acquisition negotiations flagged at HY26?
Will Promisia disclose a like-for-like Cromwell contribution to allow investors to isolate organic revenue and EBITDAF growth?

This briefing cannot assess the specific composition of the $7.3m gap between EBITDAF and PBT because the source material does not separately disclose revaluation, fair-value, or other non-operating items.

Chat

Ask about PHL FY26

Ask follow-up questions about Promisia Healthcare's FY26 result.

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Ask about PHL FY26

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Sign in to chat

Sign in to ask questions about Promisia Healthcare's FY26 result.

What specifically drove the H2 NPAT swing from near-breakeven in H1 to roughly $13.0m in H2, and how much was non-cash revaluation versus operating performance?Why does "EBITDAF of $6.6m sits well below profit before tax of $13.9m, a gap of roughly $7.3m that operating activity does not explain" matter?How strong was the cash and earnings quality in FY26?What should I watch next for PHL after FY26?

Checking account...

Data appendix

Show analytical metrics

Open to load analytical metrics.

Show key metrics table

Open to load key metrics.

Sources

Current period

PHL FY26 NZX Results Announcement

FY26 / results announcement↗

PHL FY26 Preliminary Financial Statements

FY26 / financial report↗

PHL FY26 Results Announcement

FY26 / results release↗

PHL FY26 Results Presentation

FY26 / results presentation↗

Prior comparable period

PHL 2025 Annual Report

FY25 / financial report↗

Interim context

PHL HY26 Preliminary Financial Statements

HY26 / financial report↗

PHL HY26 Results Announcement

HY26 / results release↗

PHL HY26 NZX Results Announcement

HY26 / results announcement↗

Release context

FY26 Earnings Guidance Upgrade

FY26 / commentary↗

Presentation - ASM 2025

HY26 / commentary↗

Related insights

Cross-company views selected from the metrics in this briefing.

Earnings quality and statutory distortions

PBT and NPAT growth diverged by 17.8pp, with a distortion flag in the result.

→

Leverage and balance-sheet risk

Net debt / EBITDA is 5.82x, -5.28x versus the prior comparable period.

→

Revenue growth context

Revenue growth was 29.1% for this reporting period.

→

Cash conversion quality

This result converted 96.2% of EBITDA to operating cash flow, +15.0pp versus the prior comparable period.

→
This briefing is based on available company filings and standard Annolyse calculations. It is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.

Get notified when PHL publishes next

Get the next Promisia Healthcare briefing and related NZX reporting-season updates by email.